Mobile App

Google Play Apple Store
Clinical Clip from EHA 2024 - Advancements in Myelofibrosis From Pathophysiology to Personalized Treatment Strategies
AMA/ABS/ANCC - Clinical Clip
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This clinical clip will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.
Review the activity to claim AMA/ABS/ANCC credit after completion of the brief Post-Test/Evaluation(s).

John Mascarenhas, MD John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of the Center of Excellence
for Blood Cancers and Myeloid Disorders
New York, New York

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2024 EHA Annual Congress.
Supported by an independent educational grant from CTI Biopharma Corp., a Sobi company

Launch Date: June 16, 2024
Release Date: June 16, 2024
Expiration Date: May 31, 2025

Mini Module


Change Settings